drugset / Trial / NCT04616001

IVIG in Patients With Severe COVID-19 Requiring Mechanical Ventilation

NCT04616001

Phase 4 Unknown 10 enrolled Sharp HealthCare
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this Pilot Study is to establish a hypothesis of whether or not intravenous immunoglobulin (IVIG) may impact the hospital length of stay, if started within 48 of mechanical ventilation in patients infected with SARS-CoV-2 virus.

Timeline

Start
2020-11-01
Primary completion
2021-06-30
Completion
2021-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 0.5 g/kg Intravenous

Indications